Ebola Antibodies Show Protection Potential in Animal Studies
FRIDAY, July 20, 2018 -- Two types of antibodies from the blood of Ebola survivors protected animals against strains of the virus that cause deadly infections in people, researchers report.
It may be possible to use these antibodies to create a treatment for Ebola, the researchers said.
The team, led by Dr. James Crowe of Vanderbilt University Medical Center in Nashville, and Alexander Bukreyev of University of Texas Medical Branch in Galveston, analyzed blood samples from 17 Ebola survivors. Two survivors had antibodies that prevented the virus from entering cells and causing infection in animals.
It's important to note, however, that animal studies frequently do not produce the same results in humans.
An experimental antibody-based Ebola treatment called ZMapp has shown promise in a clinical trial, but it targets only one of the five known species of Ebola virus. The new study found that the two antibodies provided protection in animals against three Ebola species.
The study, published July 17 in the journal Immunity, was funded by the U.S. National Institute of Allergy and Infectious Diseases.
© 2020 HealthDay. All rights reserved.
Posted: July 2018
Read this next
FRIDAY, Oct. 23, 2020 -- High levels of a protein that lubricates the knee joint may actually be a harbinger of impending joint disease, a surprising animal study suggests. The...
FRIDAY, Oct. 23, 2020 -- Kids growing up in poverty show the effects of being poor as early as age 5 -- especially those who are Black, a new study suggests. The research adds to...
FRIDAY, Oct. 23, 2020 -- The United States on Thursday recorded its second highest daily total of new coronavirus cases since the pandemic began, with 75,000 new infections, while...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.